Three EU firms describe progress on trial data sharing
This article was originally published in SRA
Executive Summary
In August this year, the European R&D drug industry federation EFPIA, in concert with its US counterpart PhRMA, published a set of principles for 'responsible clinical trial data sharing'1. These were a response both generally to the growing international clamour for more trial data transparency and more specifically to the European Medicines Agency's draft policy on data disclosure, which had been issued for consultation a couple of months before2,3.